Investor & Scientific Update in Stockholm November 12 and Gothenburg November 13
Isofol invites investors, shareholders, and other stakeholders to an Investor & Scientific Update in Stockholm on November 12. The principal investigator of the company’s ongoing clinical study, Professor Sebastian Stintzing of Charité – Universitätsmedizin Berlin, will discuss developments in colorectal cancer, current and future treatment options, and the latest results from the ongoing study of arfolitixorin. Professor Frits Peters at the Laboratory Medical Oncology, Amsterdam UMC and the Department of Biochemistry, Medical University of Gdansk, will provide the pharmacological background regarding the study’s optimized dosing regimen and explain why it is expected to further enhance the efficacy of arfolitixorin.
The meeting will also include an open Q&A session led by analysts from ABG Sundal Collier and Redeye, as well as presentations by Dr. Roger Tell, Chief Medical Officer, and Petter Segelman Lindqvist, Chief Executive Officer. Following the meeting, there will be an opportunity to meet and speak with members of Isofol’s Board of Directors and management team.
On November 13, a follow-up investor meeting will be held in Gothenburg to present and discuss the key messages from the Stockholm meeting.
Investor & Scientific Update, Stockholm
Thursday November 12, 14:30-16:30 CET at Tändstickspalatset, Västra Trädgårdsgatan 15, Stockholm, Sweden.
AGENDA
14.00-14.30
Registration
14.30
Opening remarks | Petter Segelman Lindqvist, CEO
14.35
Colorectal cancer today: common, lethal, and with limited treatment options | Professor and oncologist Sebastian Stintzing
14.45
Unlocking the backbone treatment – rationale behind the optimized arfolitixorin regimen | Professor Frits Peters
15.05
The ongoing arfolitixorin clinical study: Phase Ib/II design | Dr. Roger Tell
15.15 Coffee break
15.25
Update on arfolitixorin’s phase 1b results & how a successful study would impact clinical practice | Professor and oncologist Sebastian Stintzing
15.40
The Isofol case: from patient impact to value creation | Petter Segelman Lindqvist, CEO
16.00
Analyst-led Q&A with representatives from Board and Management | Dr. Georg Tigalonov-Bjerke, ABGSC; Kevin Sule, Redeye
16.30
Closing | Petter Segelman Lindqvist, CEO
16.31
Refreshments and mingle
Investor & Scientific update, Gothenburg
Friday, November 13, 14.30-16.30 CET in Isofol’s facility on Arvid Wallgrens backe 20, Gothenburg, Sweden. Representatives from the company will summarize the key messages and presentations from the Stockholm meeting and hold an open Q&A session.
Registration
Please register to attend in Stockholm or Gothenburg no later than November 2. Please note that the number of seats at the venues is limited. A video recording of the event in Stockholm will be available afterwards on the company’s website.
Last updated: